The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk.

This transcript is based on my The Year in Basic Science lecture at ENDO 2008. I reviewed current data surrounding hormone replacement therapy and the relationship between systemic estrogen plus progestin (E+P) treatment and increased breast cancer risk, and I explored the hypothesis that women who develop breast cancer while on E+P had occult, undiagnosed disease before they started therapy. Beginning with recent hormone replacement therapy data focusing on E+P and its association with breast cancer to set the stage, the lecture then reviewed our newly published data that progestins expand breast cancer stem cells. Finally, the issues of occult or undiagnosed breast cancer in presumably healthy women, and of tumor dormancy in breast cancer survivors, were brought to bear on the discussion. Taken together, these apparently disparate themes allowed me to suggest the idea that systemic progestins have the ability to reawaken cancers that were presumed to be either nonexistent or cured. To avoid this potentially devastating outcome while retaining the benefits of E+P, I advocated the use of local P delivery methods, rather than the currently popular systemic routes.
AuthorsKathryn B Horwitz
JournalMolecular endocrinology (Baltimore, Md.) (Mol Endocrinol) Vol. 22 Issue 12 Pg. 2743-50 (Dec 2008) ISSN: 0888-8809 [Print] United States
PMID18845670 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Progestins
  • Estradiol
  • Biomedical Research (trends)
  • Breast Neoplasms (etiology)
  • Drug Administration Routes
  • Drug Administration Schedule
  • Estradiol (administration & dosage)
  • Estrogen Replacement Therapy (adverse effects, methods, trends)
  • Female
  • Humans
  • Menopause (drug effects)
  • Neoplastic Stem Cells (drug effects)
  • Progestins (administration & dosage, chemistry)
  • Risk Factors
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: